Trial record 1 of 1 for:    ANBL1221
Previous Study | Return to List | Next Study

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01767194
First received: January 9, 2013
Last updated: October 14, 2014
Last verified: August 2014

January 9, 2013
October 14, 2014
February 2013
October 2015   (final data collection date for primary outcome measure)
Proportion of patients who are responders defined as patients who achieve a >= partial response (PR) per the INRC as their best overall response [ Time Frame: Up to 18 weeks ] [ Designated as safety issue: No ]
Compared between treatment arms using a Fisher's exact test.
Proportion of Patients who are Responders [ Time Frame: Four months ] [ Designated as safety issue: Yes ]
Criteria (toxicity, feasibility, Progression Free Survival) will be used to answer the primary study objective. Patient's response is to be assessed for determination of the best overall response is after the completion of the first 6 cycles.
Complete list of historical versions of study NCT01767194 on ClinicalTrials.gov Archive Site
  • Progression-free survival, defined as a relapse, progressive disease, or death attributable to tumor or treatment [ Time Frame: Time of enrollment on the study until the occurrence of the first event or until the time of last contact if no event has occurred, assessed up to 3 years ] [ Designated as safety issue: No ]
    Kaplan-Meier curves will be generated, and curves will be compared using a log-rank test.
  • Overall survival [ Time Frame: Time of enrollment on the study until the occurrence of the first event or until the time of last contact if no event has occurred, assessed up to 3 years ] [ Designated as safety issue: No ]
    Kaplan-Meier curves will be generated, and curves will be compared using a log-rank test.
  • Occurrence of unacceptable toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
  • Ability to maintain intended treatment with all agents (irinotecan hydrochloride, temozolomide and the experimental agent) without a dose reduction or going off protocol therapy for toxicity [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Overall response rate (complete response, PR, stable disease, progressive disease) according to the INRC [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Compared between treatment arms using a Fisher's exact test.
  • Response Rate [ Time Frame: Four months ] [ Designated as safety issue: Yes ]
    Responders are defined patients who achieve better than a Partial Response. Patients with Progressive Disease prior to attaining better than a Partial Response will be considered failures for the analysis of response, and go off protocol therapy. In addition, patients who meet off protocol therapy criteria due to toxicity prior to attaining better than Partial Response will also be considered treatment failures. For a given patient, this primary endpoint is binary (responder, non-responder). Patient's response is to be assessed for determination of the best overall response is after the completion of the first 6 cycles.
  • Progression-free survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    An event is defined as a relapse, progressive disease, or death attributable to tumor or treatment. Time to event for Progression free survival will be calculated from the time of enrollment on the study until the occurrence of the first event or until the time of last contact if no event has occurred. Analysis of overall survival (event = death) will also be performed. Patient's response is to be assessed for determination of the best overall response is after the completion of the first 6 cycles.
  • Toxicity [ Time Frame: Four months ] [ Designated as safety issue: Yes ]
    The toxicity endpoint will be defined as the occurrence of unacceptable toxicity per the CTCAE v4.0 toxicity grading scale. Patient's response is to be assessed for determination of the best overall response is after the completion of the first 6 cycles.
  • Feasibility [ Time Frame: Four months ] [ Designated as safety issue: No ]
    Feasibility will be defined as the ability to maintain intended treatment with all agents (irinotecan, temozolomide and the experimental agent) without a dose reduction or going off protocol therapy for toxicity. Patient's response is to be assessed for determination of the best overall response is after the completion of the first 6 cycles.
Not Provided
Not Provided
 
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma

This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or monoclonal antibody Ch14.18 work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as monoclonal antibody Ch14.18, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or monoclonal antibody Ch14.18 is more effective in treating neuroblastoma.

PRIMARY OBJECTIVES:

I. To identify whether temsirolimus or ch14.18 (monoclonal antibody Ch14.18) is the optimal therapeutic agent to consider for further testing in a future Phase III randomized trial for treatment of newly diagnosed high-risk neuroblastoma.

SECONDARY OBJECTIVES:

I. To compare the response rates (RR) for patients receiving temsirolimus or ch14.18 in combination with irinotecan (irinotecan hydrochloride) and temozolomide.

II. To compare the progression free survival (PFS) and overall survival (OS) rates for patients receiving temsirolimus or ch14.18 in combination with irinotecan and temozolomide.

III. To compare the toxicities associated with temsirolimus or ch14.18 when combined with irinotecan and temozolomide in patients with refractory, relapsed or progressive neuroblastoma.

IV. To compare the ability to maintain intended dose intensity of all agents when temsirolimus or ch14.18 is combined with irinotecan and temozolomide in patients with refractory, relapsed or progressive neuroblastoma.

V. To determine the concordance between tumor responses as defined by standard International Neuroblastoma Response Criteria (INRC) versus response per the revised INRC.

VI. To study the clinical relevance of naturally occurring anti-glycan antibodies in patients receiving ch14.18 antibody.

VII. To study the clinical relevance of natural killer (NK) receptor natural cytotoxicity triggering receptor 3 (NKp30) isoforms in patients receiving ch14.18 antibody or temsirolimus.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive temozolomide orally (PO) on days 1-5, irinotecan hydrochloride intravenously (IV) over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.

ARM II: Patients receive temozolomide and irinotecan hydrochloride as in Arm I, monoclonal antibody Ch14.18 IV over 10-20 hours on days 2-5 and sargramostim subcutaneously (SC) or IV over 2 hours on days 6-12.

In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Recurrent Neuroblastoma
  • Drug: temozolomide
    Given PO
    Other Names:
    • SCH 52365
    • Temodal
    • Temodar
    • TMZ
  • Drug: irinotecan hydrochloride
    Given IV
    Other Names:
    • Campto
    • Camptosar
    • CPT-11
    • irinotecan
    • U-101440E
  • Drug: temsirolimus
    Given IV
    Other Names:
    • CCI-779
    • cell cycle inhibitor 779
    • Torisel
  • Biological: dinutuximab
    Given IV
    Other Names:
    • Ch14.18
    • MOAB Ch14.18
    • monoclonal antibody Ch14.18
  • Biological: sargramostim
    Given SC or IV
    Other Names:
    • GM-CSF
    • Leukine
    • Prokine
  • Other: laboratory biomarker analysis
    Optional correlative studies
  • Experimental: Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)
    Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
    Interventions:
    • Drug: temozolomide
    • Drug: irinotecan hydrochloride
    • Drug: temsirolimus
    • Other: laboratory biomarker analysis
  • Experimental: Arm II (temozolomide, irinotecan hydrochloride, Ch14.18)
    Patients receive temozolomide and irinotecan hydrochloride as in Arm I, monoclonal antibody Ch14.18 IV over 10-20 hours on days 2-5 and sargramostim SC or IV over 2 hours on days 6-12.
    Interventions:
    • Drug: temozolomide
    • Drug: irinotecan hydrochloride
    • Biological: dinutuximab
    • Biological: sargramostim
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
74
Not Provided
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines (i.e., > 2 x upper limit of normal [ULN]), at the time of initial diagnosis
  • For the purposes of this study, aggressive multidrug chemotherapy is defined as chemotherapy including 2 or more agents that must include an alkylating agent and a platinum-containing compound; patients must have ONE of the following:

    • First episode of recurrent disease following completion of aggressive multi-drug frontline therapy
    • First episode of progressive disease during aggressive multi-drug frontline therapy
    • Primary resistant/refractory disease detected at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (examples include A3973, ANBL0532, ANBL09P1, etc.)
  • Patients must have at least ONE of the following:

    • Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan obtained within 3 weeks prior to study entry; measurable is defined as >= 10 mm in at least one dimension on spiral/helical CT that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased fludeoxyglucose (FDG) uptake on positron emission tomography (PET) scan
    • MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site; this site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction
    • Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma; biopsy is not required for patients who have new site of soft tissue disease (radiographic evidence of disease progression) regardless of whether progression occurs while receiving therapy or after completion of therapy
    • Note: Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study
  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
  • Patients must have received frontline therapy (including surgery, chemotherapy, autologous stem cell transplant [SCT] +/- MIBG, immunotherapy, radiotherapy, and retinoids) but may NOT have received second line chemotherapy for resistant/refractory, relapsed disease or progressive disease
  • At least 14 days must have elapsed since completion of myelosuppressive therapy
  • At least 7 days must have elapsed since the completion of therapy with a non-myelosuppressive biologic agent or retinoid
  • No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this study
  • Patients are eligible >= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met
  • Patients are eligible >= 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met
  • Subjects who have previously received anti-disialoganglioside (GD2) monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible
  • Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days of entry on this study; seven days must have elapsed since administration of a short acting myeloid growth factor
  • Peripheral absolute neutrophil count (ANC) >= 750/uL
  • Platelet count >= 75,000/uL (transfusion independent)
  • Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity
  • Creatinine clearance or estimated radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or
  • A serum creatinine =< upper limit of normal (ULN) based on age/gender as follows:

    • Age 1 month to < 6 months: 0.4 for males, 0.4 for females
    • Age 6 months to < 1 year: 0.5 for males, 0.5 for females
    • Age 1 to < 2 years: 0.6 for males, 0.6 for females
    • Age 2 to < 6 years: 0.8 for males, 0.8 for females
    • Age 6 to < 10 years: 1 for males, 1 for females
    • Age 10 to < 13 years: 1.2 for males, 1.2 for females
    • Age 13 to < 16 years: 1.5 for males, 1.4 for females
    • Age >= 16 years: 1.7 for males, 1.4 for females
  • Total bilirubin =< 1.5 x ULN for age AND
  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5.0 x ULN for age (=< 225 U/L); for the purpose of this study, the ULN for SGPT is 45 U/L
  • Adequate central nervous system function defined as:

    • Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment
    • Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants
    • CNS toxicity =< grade 2
  • Shortening fraction of >= 27% by echocardiogram (ECHO) OR
  • Ejection fraction >= 50% by ECHO or gated radionuclide study
  • Adequate coagulation defined as:

    • Prothrombin time (PT) =< 1.2 x upper limit of normal
  • Serum lipids within acceptable range:

    • Serum triglyceride level =< 300 mg/dL and serum cholesterol level =< 300 mg/dL; If non-fasting values exceed these levels, lipid testing should be repeated in the fasting state
  • Adequate pulmonary function defined as:

    • No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry; normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung of carbon monoxide [DLCO]) are required if there is a clinical indication for determination; for patients who do not have respiratory symptoms, full pulmonary function tests (PFTs) are NOT required

Exclusion Criteria:

  • Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study; based on the established teratogenic potential of alkylating agents and temsirolimus, pregnant women will be excluded from this study; because of potential risks to breastfed infants due to drug metabolites that could be excreted in breast milk, female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study; females of childbearing potential must have a negative pregnancy test to be eligible for this study
  • Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study
  • Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency
  • Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible
  • Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma
  • Patients with symptoms of congestive heart failure are not eligible
  • Patients must not have >= grade 2 diarrhea
  • Patients must not have uncontrolled infection
  • Patients who have received prior therapy with an mammalian target of rapamycin (mTOR) inhibitor in combination with cytotoxic chemotherapy are not eligible
  • Patients with a history of significant allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus are not eligible
  • Patients with a history of grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of the anti-GD2 therapy are not eligible
  • Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible
Both
Not Provided
No
United States,   Australia,   Canada,   New Zealand
 
NCT01767194
NCI-2012-03125, NCI-2012-03125, COG-ANBL1221, CDR0000745188, ANBL1221, ANBL1221, U10CA180886, U10CA098543
Yes
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Rajen Mody Children's Oncology Group
National Cancer Institute (NCI)
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP